Pdt Partners, LLC Rubius Therapeutics, Inc. Transaction History

Pdt Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$9.68 - $17.74 $638,792 - $1.17 Million	-65,991 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $353,742 - $520,765	20,099 Added 43.8%	65,991 $1.18 Million
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $662,724 - $846,417	29,772 Added 184.69%	45,892 $1.12 Million
Q1 2021 May 17, 2021	SELL	$8.02 - $32.01 $54,471 - $217,411	-6,792 Reduced 29.64%	16,120 $427,000
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $112,467 - $232,113	-26,588 Reduced 53.71%	22,912 $174,000

Q3 2020 Nov 16, 2020	SELL	$4.65 - $6.25 $47,625 - $64,012	-10,242 Reduced 17.14%	49,500 $248,000
Q2 2020 Aug 14, 2020	BUY	$4.01 - $6.88 $239,565 - $411,024	59,742 New	59,742 $357,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.